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1. Introduction and aims 
1.1 Design and synthesis of new fumitremorgin analogues 
The human ABCG2 protein belongs to the ABCG subfamily of ABC transporters. 
The members of this subfamily are ABC half-transporters, they contain only one ABC and 
one transmembrane domain.  
ABCG2 protein (placenta-specific ABC transporter/mitoxantrone resistance-
associated protein/breast cancer resistance protein) has been identified recently as a candidate 
protein responsible for cancer multidrog resistance. The over expression of ABCG2 was 
found in several drug-selected cell lines and in tumorous tissues of patients. The activity of 
the human ABCG2 was suggested to be the major cellular defense mechanism against the 
cytotoxic drug, mitoxantrone, also several other drugs have been indicated as potential 
substrates of this drug pump. 
Numerous ABCG2-specific inhibitors have been reported in the past decade. Such 
inhibitors include the antifungal agent fumitremorgin C (TFC), GF120918, Gleevec (imatinib 
mesylate), and so on (Scheme 1.). FTC, a member of a group of indole alkaloids, is a specific, 
selective inhibitor of the breast cancer resistance protein (BCRP/ABCG2). 
 
 
Scheme 1. Some BCRP inhibitors 
 
Our aims were to find a convenient strategy for optimizing Ko134 (published in 
literature) synthesis and to design new fumitremorgin analogues in order to increase 
specificity, chemical and metabolic stability of the original Ko134.  
 
1.2 Synthesis of modified miniproteins 
Understanding the mechanism behind protein folding, which is one of the most 
fundamental biochemical process, is proved to be a challenging task. Miniproteins represent 
simple and useful model systems in order to study the structural determinants of protein 
folding and stability. Miniproteins are adequate models to investigate various protein-
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structure modifying effects such as temperature, pH, point mutation(s), H-bonds, salt bridges, 
molecular packing, etc.. TC5b, a 20-residue Trp-cage protein is one of the smallest of such 
models with a stable 3D fold, understanding the stability and folding of globular proteins. 
Our aims were to design and synthesize TC5b miniprotein mutants, to better 
understand the global stability of the Trp-cage minipotein. Furthermore, Trp-cage miniprotein 
has been used to investigate the fold stabilizing effect of a salt bridge (Asp9-Arg16). Salt 
bridges are important as they contribute to protein folding, structure, residual flexibility and 
function. Salt bridges may increase the specificity of folding by reducing the number of way 
of molecular packing.  
 
1.3 Synthesis of glycopeptides 
Glycopeptides play a crucial role in various biological functions, especially in 
biological recognition events, signal transduction, and immune response. The carbohydrate 
moieties are attached through the oxygen in the side chain of serine/threonine in O-linked 
glycoproteins or through the carboxyamide nitrogen of asparagine in case of N-linked 
glycoproteins.  
The rational preparation of the glycosylated peptides is still one of the most 
challenging tasks of peptide chemistry especially of those having oligosaccharide moieties. 
There are two main strategies: the stepwise approach (normally proceeds through a protected 
glycosylated amino acid intermediate which usually serves as the building block for a solid-
phase construction of a peptide sequence) and the convergent method (the required 
carbohydrate chain and peptide are each built independently, and the amide or ester linkage is 
created in the synthesis). Both of them can be implemented in liquid or solid-phase. 
Our aim was to design a mixed Fmoc/Boc synthesis strategy for the preparation of 
glycopeptides using a mild and selective deprotecting agent tin (IV)-chloride for the 
incorporation of Boc-protected glycosylated asparagine and serin derivatives. 
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1.4 Synthesis of precursors for radiopharmacon preparation 
Alzheimer's disease is characterized by the presence of β-amyloid fibril formation. 
The inhibition of this peptide accumulation may be a prevention method for Alzheimer's 
disease. Beta-sheet breakers constitute a new class of drugs that are designed to specifically 
bind amyloid-beta peptide and block and/or reverse this abnormal conformational change. 
Several classes of molecules have been reported to inhibit β-amyloid fibril formation for 
example: Congo Red, some short fragments of the Aβ (RVVIA, LPFFD, LPYFD), curcumin 
(Scheme 2.). 
Curcumin (diferulomethane) is a low molecular weight molecule with potent 
antioxidant and anti-inflammatory activities that has a favorable toxicity profile and is under 
development as a potential cancer chemotherapeutic 
agent. The phenolic yellow curry pigment curcumin 
directly binds small                                 
               Scheme 2.                 β-amyloid species to block aggregation and 
fibril formation in vitro and in vivo. These data suggest that low dose curcumin effectively 
disaggregates Aβ as well as prevents fibril and oligomer formation, supporting the rationale 
for curcumin use in clinical trials preventing or treating Alzheimer’s disease. 
Our aims were to design and synthesize precursors which can penetrate the blood 
brain barrier directly binds β-amyloid plaques and with the convenient Medical Image 
Processing which increases the chance of early detection of Alzheimer’s disease. We wanted 
to design a combined solid and solution phase synthesis strategy for the incorporation of the 
curcumin, DOTA (Scheme 3.), N-carboxymethyl-histidine to the KLPYFD and LPYFD 
(short fragment of β-amyloid) peptides. 
 
                         Scheme 3. 
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2. Results and discussion 
2.1 Design and synthesis of new fumitremorgin analogues 
To improve the specificity and selectivity of Ko134 (fumitremorgin analogue) while 
eliminating the potential for toxicity, we have designed and synthesized a new class of FTC 
analogues using solid and solution phase synthesis strategy. To prepare larger quantities of 
Ko134 (published in literature) for in vivo studies, we have developed a straightforward and 
efficient solution phase synthesis strategy for the preparation of Ko134 inhibitor, using both 
RP-HPLC and column chromatography.  
First we applied the solid phase synthesis strategy for the preparation of new 
fumitremorgin analogues. In solid phase, the elongation of the peptide chain with a Fmoc-
protected amino acid to the tetrahydro-β-carboline’s secondary nitrogen wasn’t successful 
under various reaction conditions, even with the most potent coupling reagents: TCFH, 
TFFH, CIP, HATU. Therefore we decided to synthesize fumitremorgin analogues in solution 
phase. In solution phase incorporation of the Fmoc- and Boc-protected amino acids was 
successful using TCFH coupling reagent. 
The FTC-Ko family proved to be a good starting point since these compounds 
displayed significant specificity that was confirmed in this study (Fig 25.). Our data show that 
the FTC type diketo-piperazine ring structure is essential for activity as tricyclic analogues 
IIIa-IIId showed no activity in the Hoechst assay. On the other hand, compounds that 
pereserved the diketo-piperazine ring structure were all active provided they had a 3S, 6S, 
12aS configuration (Fig 25.). Based on previous data, the compounds with 3S, 6R, 12aS 
configuration were inactive as expected except perhaps the partially active 3e5 (3S,6R,12aS). 
But even in that case 3e5 (3S,6S,12aS) the diastereoisomeric pair was more than 110-fold 
more potent with IC50 values of 16.7 µM and 0.14 µM respectively. Remarkably, 
stereospecificity (3S, 6S, 12aS vs 3S, 6R, 12aS) observed in ABCG2 inhibition was 
completely absent in inhibition of ABCB1 and ABCC1 (Fig 25.). Moreover, the compounds 
with 3S, 6R, 12aS configuration did not exhibit ABCG2 specificity over ABCB1 and 
ABCC1. The fact that configuration at position 6 alone confers specificity for ABCG2 over 
ABCB1 and ABCC1 has not been described before. This specificity confined to a single 
chiral center is quite unexpected considering the previosly described broad substrate 
specificity of these ABC transporters.  
The Ko134 in vivo biological analysis are in progress. 
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2.2 Synthesis of modified miniproteins 
Hudaky et al. designed a new variant of TC6b, differs only by a methylene group 
from TC5b. Tc6b exhibits enhanced heat stability and adopts a stable fold at physiological 
temperature. 
Based on this salt bridge optimized model system TC5b_D9E 
(NLYIQWLKEGGPSSGRPPPS) new miniprotein analogues were synthesized: TC5b_D9N 
(NLYIQWLKNGGPSSGRPPPS), TC5b_R16A (NLYIQWLKDGGPSSGAPPPS), 
TC5b_D9N_R16A (NLYIQWLKNGGPSSGAPPPS), TC5b_D9S (NLYIQWLKSGGPSSGR 
PPPS), TC5b_R16hR (NLYIQWLKDGGPSSGhRPPPS), TC5b_D9AaD_R16K 
(NLYIQWLKAaDGGPSSGKPPPS). The peptides were synthesized by solid-phase 
technique utilizing Fmoc-chemistry. 
In order to monitor the structure stabilizing factor of the salt bridge Asp9-Arg16, the 
new TC5b mutants were studied at two different pHs (~3,0 and ~7,0), over a wide range of 
temperature relevant for proteins (55 ≤ T ≤ 85°C). Secondary structural changes recorded by 
ECD data were jointly analyzed and quantified by the deconvolution program CCA+. In 
order to locate structural differences at an atomic level in the fully folded states, high 
resolution H1-H1 NMR studies were completed (T= 280 K) both at neutral (6,5 ≤ pH ≤ 3,2) 
and acidic (2,8 ≤ pH ≤ 3,2) pH conditions. With the above model miniproteins and tools in 
hand, our aim was to evaluate the role of salt bridge on protein fold stability. 
During the structural analysis, we found that the salt bridge of the Trp-cage scaffold is 
not an isolated structure stabilizing element but rather an integrated part of the foldamer. In 
case of the examined mutants the observed stability tendencies can be understand by 
considering three specific, but coupled interactions: electrostatic, helix-stabilizing (QxxxY) 
and hydrophobic [of the –(CH2)3– arm of Arg16 with the indole ring of Trp6]. Based on the 
herein reported mutation studies it seems that the interaction network of the –(CH2)3– arm of 
Arg16 residue is of higher importance, than the one operative between the negatively charged 
Asp9/Glu9 and the positively charged guanidine group. The elimination of one of the salt 
bridge forming partner (TC5b_D9S, TC5b_D9N) is less drastic than the elimination of the 
hydrophobic arm of Arg16 (TC5b_R16A). 
The deconvolution of ECD spectra and the analysis of the acidic NMR spectra 
revealed that the melting scenario of the Trp-cage is not a simple two-state mechanism but 
rather a more comlex process with at least one intermedier state. 
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Protein aggregation and misfolding of proteins can be linked to the origin of many 
conformational diseases which can be either genetic or spontaneous. The proteins involved 
can either have an unstructured or lineal unfolded form such as in Alzheimer's and 
Parkinson's disease or Type II Diabetes, or can be globular, showing a folded 3D-structure. 
Protein aggregation is a major importance in biomedicine, yet it is not well understand. In the 
framework of our research project on the structural analysis of TC5b analogues we observed 
aggregation in case of TC5b_D9N and other TC5b phosphorylated mutants. Consequently, 
TC5b structure can serve as a good model for Alzheimer’s aggregates. Based on our previous 
studies new TC5b analogues were synthesized for further structural investigations: 
TC5b_D9Q (NLYIQWLKQGGPSSGRPPPS), TC5b_S14E (NLYIQWLKDGGPSE 
GRPPPS), TC5b_S14Q (NLYIQWLKNGGPSQGRPPPS), TC5b_S20E(NLYIQWLKNG 
GPSSGRPPPE), TC5b_S20Q (NLYIQWLKNGGPSSGRPPPQ). 
 
2.3 Synthesis of glycopeptides 
For the preparation of glycopeptides a mixed Fmoc/Boc solid-phase synthesis strategy 
was applied by using a new, mild and selective Boc deprotecting agent.  
According to literature the Fmoc-protected glycosylated asparagine and serine 
derivatives proved to be suitable building blocks for the solid-phase peptide synthesis. In 
some cases the preparation of Boc-protected glycosylated amino acid building blocks are 
more convenient than the Fmoc protected ones. For the incorporation of the Boc-protected 
glycosylated amino acid derivatives in the model peptides selective Boc deprotecting agent 
tin(IV) chloride was used. The glycopeptides were synthesized using Fmoc chemistry on a 
TFA cleavable Rink-amide MBHA resin. According to our investigations other resins 
commonly used in Fmoc chemistry (Rink amide, 2-chlorotrityl resin, Wang resin) showed 
leakage of the peptide from the resin during cleavage with tin(IV) chloride, except  the Rink-
amide MBHA.   
As model peptides we used a shorter fragment of the Trp-cage miniprotein (Leu-Lys-
Asn*-Gly-Gly-Pro) and an aggrecan fragment, from the most glycosylated region of the 
protein (Gly-Val-Glu-Asp-Ile-Ser*-Gly-Leu-Pro-Ser-Gly). (Where * is site of glycosylation).  
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                            Scheme 4. 
 
For the synthesis of Leu-Lys-[GlcNAc(β1-N)]Asn-Gly-Gly-Pro-NH2,Leu-Lys-
[GlcNAc(β1-4)GlcNAc (β1-N)]Asn-Gly-Gly-Pro-NH2, Leu-Lys-[Man(β14)GlcNAc(β1-
4)GlcNAc(β1-N)]Asn-Gly-Gly-Pro-NH2 Rink amide-MBHA resin was applied. As building 
blocks N,α-Boc-protected glycosylated asparagine derivatives were used (Scheme 4.). The 
first 3 amino acids were incorporated using Fmoc strategy. After coupling of Boc-protected 
glycosylated aspartic acid derivatives, the resin was treated twice with 0.2 M SnCl4, giving 
the resin a red colour due to complex formation with SnCl4. Coupling of the last two amino 
acid was performed using Fmoc chemistry.  
The synthesis strategy of H-Gly-Val-Glu-Asp-Ile-[Xil(β1-O)]Ser-Gly-Leu-Pro-
Ser(Bzl)-Gly-NH2 was the same as in case of N-glycopeptides in exception that in this case 
the peptide contains a glycosylated serin derivative with three unprotected hydroxyl 
functional groups and several trifunctional amino acids, which side chains must be protected 
during the synthesis. Based on our earlier research the Ser-Bzl, Ser(Xil)-Bz, Glu-, Asp-
ODmab (Scheme 5.) protecting group combination was suitable for the preparation of this 
glycopeptide. As building block N,α-Boc-protected serin derivative was used (Scheme 6.). 
Dmab-deprotection was made with a solution of hydrazine-hydrate, on resin. Bz-deprotection 
was made in solution-phase with hydrazine-hydrate. 
 
            
       Scheme 5. Dmab protecting group   Scheme 6.   Boc-Ser[Xil(OBz)3]-OH 
 
In summary we found a convenient solid-phase synthesis strategy for the preparation 
of the above glycosylated-hexapeptide conjugates. I have developed a strategy that combines 
the Fmoc and Boc SPPS approaches for the preparation of N- and O-glycopeptides in high 
purity and reasonable yield, using SnCl4 for Boc deprotection, which leaves the acid sensitive 
glycosidic bonds intact. 
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2.3 Synthesis of precursors for radiopharmacon preparation  
For the preparation of the precursors, amyloid peptide mimics LPYFD, KLPYFD, 
curcumin, DOTA and N-carboxymethyl-histidine were chosen. 
In the framework of our project on the synthesis of precursors in solution phase, 
phenolic hidroxyl group of the curcumin was alkylated with ethyl bromoacetate. The 
resulting curcumin derivative was then used to create a curcumin-peptide, but incorporation 
wasn’t successful.  
Therefore we decided to modify the strategy for the incorporation of curcumin in the 
model peptide by using a new mixed solution and solid phase synthesis strategy. First the 
short fragments of the β-amyloid peptide LPYFD and KLPYFD were synthesized manually 
using Fmoc peptide synthesis protocols. Henceforth, bromo-acetyl peptide was used for 
coupling with curcumin (in solid phase) then curcumin-peptide was acylated with DOTA in 
solution phase. For the incorporation of N-carmoxymethyl histidine the same synthesis 
strategy was used, as well the synthesized bromo-acetyl peptide was used for coupling with 
N-carmoxymethyl histidine. 
In summary, we found a convenient strategy for the preparation of the above 
precursors, using a combined solid and solution phase synthesis. With this combined 
technique incorporation of the curcumin, DOTA and N-carboxymethyl-histidine was 
successful. Analysis concerning the new biological activity are in progress. 
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